Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763848 | 1.00 | BTN3A1 (0.32) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL3616995 | 1.00 | BTN3A1 (0.32) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL4217873 | 0.86 | NOS1 (0.33) | BTN3A1 | |
| SCHEMBL30980082 | 0.83 | IDO1 (0.34) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL19699429 | 0.83 | IDO1 (0.34) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL1067509 | 0.83 | IDO1 (0.34) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL1067514 | 0.83 | IDO1 (0.34) | BTN3A1KIF11CA1CA2 | |
| SCHEMBL20591675 | 0.81 | NOS3 (0.38) | KIF11 | |
| SCHEMBL21224417 | 0.81 | — | — | |
| SCHEMBL21224419 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039257-B1 | PHARMACEUTICAL COMPOSITION AND KIT CONTAINING A PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM BETA-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE | FUJIFILM CORP (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-12312349-B2 | Apoptosis-inducing agents | FOCHON PHARMACEUTICALS, LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| US-12286440-B2 | Penam derivative or salt thereof, pharmaceutical composition, and applications thereof | FUJIFILM CORPORATION (JP) | 2025-04-29 | — | — | US | disclosed |
| CN-114531850-B | Pharmaceutical composition and kit characterized by containing novel penicillin derivative or salt thereof and at least 1 compound selected from beta-lactamase inhibitory compound and antibacterial compound or salt thereof | 富士胶片株式会社 | 2024-08-06 | — | — | CN | disclosed |
| EP-4119560-B1 | APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-111954673-B | New penam derivatives or salts thereof, pharmaceutical compositions and uses thereof | 富士胶片株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-116589459-A | Apoptosis inducer | 重庆复创医药研究有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023098831-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | 嘉兴优博生物技术有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-110546151-B | Apoptosis inducer | 重庆复创医药研究有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-4119560-A1 | APOPTOSIS-INDUCING AGENTS | Shanghai Fochon Pharmaceutical Co., Ltd. (CN) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021066149-A1 | PHARMACEUTICAL COMPOSITION AND KIT CHARACTERIZED BY CONTAINING NOVEL PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM Β-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE | 富士フイルム株式会社 | 2021-04-08 | — | — | WO | disclosed |
| EP-3778609-A1 | NOVEL PENAM DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | FUJIFILM Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20210024543-A1 | NOVEL PENAM DERIVATIVE OR SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2021-01-28 | — | — | US | disclosed |
| US-20210024543-A1 | NOVEL PENAM DERIVATIVE OR SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2021-01-28 | — | — | US | disclosed |
| CN-111954673-A | Novel penam derivative or salt thereof, pharmaceutical composition, and use thereof | 富士胶片株式会社 | 2020-11-17 | — | — | CN | disclosed |
| US-20200115379-A1 | APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| CN-110546151-A | apoptosis-inducing agent | SHANGHAI FOCHON PHARMACEUTICAL CO LTD | 2019-12-06 | — | — | CN | disclosed |
| WO-2019194306-A1 | NOVEL PENAM DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 富士フイルム株式会社 | 2019-10-10 | — | — | WO | disclosed |
| US-4751299-A | Optically active β-lactams and method of their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0144840-A2 | Optically active beta-lactams and method of their production | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312349-B2 | Apoptosis-inducing agents | BCL2, BAX, BAD | BTN3A1 3476/4885KIF11 4485/4885CA1 2744/4885 |
| US-20200115379-A1 | APOPTOSIS-INDUCING AGENTS | BCL2, BAX, BAD | BTN3A1 3476/4885KIF11 4485/4885CA1 2744/4885 |
| US-20210024543-A1 | NOVEL PENAM DERIVATIVE OR SALT THEREOF, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS THEREOF | CFTR, SLC11A2, SLC20A1 | BTN3A1 3879/4885KIF11 2569/4885CA1 4736/4885 |
| US-12286440-B2 | Penam derivative or salt thereof, pharmaceutical composition, and applications thereof | CFTR, SLC11A2, REN | BTN3A1 3681/4885KIF11 2689/4885CA1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.